- Home
- UPXI vs ARTL Comparison
UPXI vs ARTL Comparison
Compare UPXI & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- ARTL
- Stock Information
- Founded
- UPXI 2018
- ARTL 2011
- Country
- UPXI United States
- ARTL United States
- Employees
- UPXI N/A
- ARTL N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- ARTL Biotechnology: Pharmaceutical Preparations
- Sector
- UPXI Health Care
- ARTL Health Care
- Exchange
- UPXI Nasdaq
- ARTL Nasdaq
- Market Cap
- UPXI 3.6M
- ARTL 3.1M
- IPO Year
- UPXI 2021
- ARTL N/A
- Fundamental
- Price
- UPXI $15.51
- ARTL $1.04
- Analyst Decision
- UPXI
- ARTL Strong Buy
- Analyst Count
- UPXI 0
- ARTL 2
- Target Price
- UPXI N/A
- ARTL $5.50
- AVG Volume (30 Days)
- UPXI 6.5M
- ARTL 1.2M
- Earning Date
- UPXI 05-07-2025
- ARTL 05-12-2025
- Dividend Yield
- UPXI N/A
- ARTL N/A
- EPS Growth
- UPXI N/A
- ARTL N/A
- EPS
- UPXI N/A
- ARTL N/A
- Revenue
- UPXI $18,625,089.00
- ARTL N/A
- Revenue This Year
- UPXI $299.03
- ARTL N/A
- Revenue Next Year
- UPXI N/A
- ARTL N/A
- P/E Ratio
- UPXI N/A
- ARTL N/A
- Revenue Growth
- UPXI 4.75
- ARTL N/A
- 52 Week Low
- UPXI $1.90
- ARTL $0.82
- 52 Week High
- UPXI $22.53
- ARTL $1.59
- Technical
- Relative Strength Index (RSI)
- UPXI 88.68
- ARTL 54.43
- Support Level
- UPXI $9.81
- ARTL $0.88
- Resistance Level
- UPXI $22.00
- ARTL $1.16
- Average True Range (ATR)
- UPXI 2.41
- ARTL 0.14
- MACD
- UPXI 1.41
- ARTL 0.02
- Stochastic Oscillator
- UPXI 65.96
- ARTL 37.93
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. It reaches consumers through its direct-to-consumer network, wholesale partnerships, and prominent third-party platforms like Amazon.
About ARTL Artelo Biosciences Inc.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.